Niu, N., Xue, J., Chen, G., Qiu, F., Xu, Q., Zheng, X., Liu, C., Zhao, Y., Gu, X., Zhao, Y., Xu, H., Zhang, H., He, G., Li, K., Li, P., Chen, X., Li, Y., Wang, S., Zhu, D., Liu, T., Xing, F., Xu, Y., Han, Y., Tang, M., Liu, M., Jiao, G., Jiang, X., Yuen, T., Pang, Z., Liu, C. (2025). Neoadjuvant ARX788 plus pyrotinib versus trastuzumab, pertuzumab, docetaxel and carboplatin for HER2-positive breast cancer: a randomised phase 2b trial. Nature Communications. https://doi.org/10.1038/s41467-025-61213-2